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A systems biology approach to investigate the mechanism of
action of trabectedin in a model of myelomonocytic leukemia
L Mannarino1, L Paracchini1, I Craparotta1, M Romano1, S Marchini1, R Gatta1,2, E Erba1, L Clivio1, C Romualdi3, M D’Incalci1,
L Beltrame1,5 and L Pattini4,5
This study was designed to investigate the mode of action of trabectedin in myelomonocytic leukemia cells by applying systems
biology approaches to mine gene expression proﬁling data and pharmacological assessment of the cellular effects. Signiﬁcant
enrichment was found in regulons of target genes inferred for speciﬁc transcription factors, among which MAFB was the most
upregulated after treatment and was central in the transcriptional network likely to be relevant for the speciﬁc therapeutic effects
of trabectedin against myelomonocytic cells. Using the Connectivity Map, similarity among transcriptional signatures elicited by
treatment with different compounds was investigated, showing a high degree of similarity between transcriptional signatures of
trabectedin and those of the topoisomerase I inhibitor, irinotecan, and an anti-dopaminergic antagonist, thioridazine. The study
highlights the potential importance of systems biology approaches to generate new hypotheses that are experimentally testable to
deﬁne the speciﬁcity of the mechanism of action of drugs.
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INTRODUCTION
Trabectedin (ET-743) is a DNA minor-groove binding agent
originally isolated from the Caribbean tunicate Ecteinascidia
turbinata and recently obtained by chemical synthesis.1 It is
approved for the second line therapy of soft-tissue sarcoma and
ovarian cancer in Europe, and several other countries and is
currently under evaluation in many other malignancies. It has a
complex mode of action involving DNA repair and transcription
mechanisms, resulting in cytotoxic effects with perturbations of
the cell cycle and cell death (D'Incalci et al.2, for a review). Previous
studies have indicated that trabectedin is cytotoxic not only
against cancer cells, but exerts also a selective activity against
monocytes and macrophages.3,4 This ﬁnding was of interest as
macrophages are quiescent cells generally considered very
resistant to most anticancer drugs. These observations led to
discover that trabectedin has the ability to modulate the tumor
microenvironment,5 that was proposed to be relevant also for its
antitumor activity.
Recently, the drug has shown a signiﬁcant cytotoxic activity
against Juvenile and Chronic myelomonocytic cells taken from
patients suffering from these diseases for which there is an urgent
need of novel effective therapies.6 This observation prompted us
to investigate the mode of action of trabectedin in a representa-
tive myelomonocytic leukemia cell line. We have applied a
systems biology approach to study gene expression proﬁles of
treated cells integrated with speciﬁc experiments aimed at
assessing their phenotype. The results indicate that the drug has
the ability to modulate speciﬁc pathways regulating cell cycle and
cell death of myelomonocyctic leukemic cells, thus reinforcing the




Trabectedin was supplied by PharmaMar (Colmenar Viejo, Madrid, Spain)
and was stocked in dimethyl sulfoxide at a concentration of 1 mM and
stored at − 20 °C. 5-azacytidine, thioridazine and SN-38 were purchased
from Sigma (St Louis, MO, USA). All drugs were diluted in medium just
before use.
Cell growth and treatment
MV-4-11, a biphenotypic B myelomonocytic leukemia, cell line was grown
in RPMI-1640 medium (Life Technologies,Carlsbad, CA, USA) supplemented
with 10% of fetal bovine serum HyClone (Thermo Scientiﬁc, Waltham, MA,
USA) and 1% L-glutamine 200 nM (Life Technologies, Milan, Italy). Cells were
maintained at 37 °C and in a humidiﬁed atmosphere at 5% CO2 in 25 cm
2
ﬂasks (Iwaky Bibby Sterilin, Staffordshire, UK). Exponentially growing cells
were treated with different concentrations of either trabectedin or 5-
azacytidine, or thioridazine, or SN-38. Cell growth inhibition was measured
by counting the number of cells by using Coulter Counter (Beckman
Coulter, Brea, CA, USA).
Cell cycle perturbation and apoptotic cell death by ﬂow cytometry
To evaluate the cell cycle perturbation, treated and untreated cells were
ﬁxed in ethanol 70%, washed in cold phosphate-buffered saline and the
DNA was stained overnight with 1 ml of a solution containing 12,5 g ml− 1
propidium iodide and 12,5 μl of RNAse 1 mg ml− 1. To detect apoptosis,
MV-4-11 control and treated cells were processed by using the Annexin-V
detection kit FITC (Affymetrix eBioscience, St Clara, CA, USA), following the
manufacturer’s protocol. Flow cytometric analysis was performed on
10 000 events by using FACS Calibur instrument (Becton Dickinson,
Franklin Lakes, NJ, USA).
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Microarray experiment and data quantiﬁcation
RNA was extracted using a commercial kit (miRNeasy, QIAGEN, Milan, Italy),
according to the manufacturer's instructions. 100 ng of total RNA were
reverse-transcribed into Cy3-labeled cRNA using LowInput QuickAmp
labeling kit (Agilent Technologies, Palo Alto, CA, USA), and hybridized onto
commercially available array platforms as previously described.7 Three
technical replicates were used for each condition. Raw data from Agilent
Feature Extraction version 11 were preprocessed removing features
marked as unreliable by the scanning software and arrays were normalized
using the ‘quantile’ method.8 Raw data are available on the ArrayExpress
database, under accession ID E-MTAB-2978.
Differential expression analysis
The R package limma (Linear models for microarray analysis)9 was used to
determine differentially expressed genes (DEGs) applying a correction for
technical replicates. A time-course analysis was accomplished: DEGs both
for trabectedin and 5-azacytidine treatment were calculated by comparing
6 h versus control and 24 h versus 6 h samples. Untreated samples were
used as control. Genes with a false discovery rate (FDR)10 corrected
P-value (q-value) ⩽ 0.01 were deemed signiﬁcant.
Functional annotation analysis
Pathway analysis was performed using a topology-based approach,11
with Reactome12 and the Pathway Interaction Database (PID13) as
annotation sources. Pathways were deemed signiﬁcant if their q-value
was ⩽ 0.05.
Gene Ontology functional enrichment was performed by querying the
Gene Ontology source14 using the biological process ontology on both
upregulated and downregulated genes differentially expressed by both
the treatment with trabectedin and the drugs resulted from CMAP analysis.
Figure 1. (a) Growth inhibition induced by different concentrations of trabectedin (Trab) or 5-azacytidine (5-Aza). 5 nM and 2.5 μM correspond
to the half-maximal inhibitory concentrations (IC50) for trabectedin and 5-azacytidine, respectively. (b) Cell cycle perturbation induced by 5 nM
trabectedin (B) and 2.5 μM 5-azacytidine (C) evaluated at 24 h after drug-treatment compared to the control cells (A). (c) Apoptosis induced by
5 nM trabectedin (F) and 2.5 μM 5-azacytidine (G) evaluated at 24 h after drug-treatment compared with the control cells (E). P.I., propidium
iodide. R1, viable cells; R2, early apoptosis; R3, late apoptosis; R4, necrosis.
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Nominal P-values were corrected with the Bonferroni method (corrected
P-values⩽ 0.01).
Master regulator analysis
A master regulator analysis was applied to infer the transcription factors
mainly involved in speciﬁc deregulation of gene expression of drug
responding cells. To this aim, a transcriptional network was reverse
engineered from a publicly available clinical database of expression
proﬁles of 22215 genes related to 293 patients affected with acute myeloid
leukemia (NCBI Gene Expression Omnibus GSE1159) starting from a list of
all known human transcription factors.15 The ensemble of transcriptionally
correlated genes (regulon) for each transcription factor was estimated
through the ARACNE software,16 based on the mutual information
operator. For each regulon, only positively (sign assessed according to
Pearson’s correlation coefﬁcient) correlated targets were considered and
gene sets with at least 20 genes were retained. The regulons obtained
were used for Gene Set Enrichment Analysis17 comparing gene expression
data from either trabectedin or 5-azacytidine treatments at 6 and 24 h with
control samples (0 h) independently, with default parameters.
Search for similar drug proﬁles
We queried the Connectivity MAP (CMAP18) to search for drug responses
with gene expression proﬁles similar to trabectedin response. Up- and
downregulated genes related to the treatment with trabectedin at 6 h
were used as input, converting Agilent probes identiﬁers in Affymetrix
GeneChip Human Genome U133A Array identiﬁers using the conversion ID
tool provided by DAVID.19
RESULTS AND DISCUSSION
In the present study, we show that trabectedin is very effective in
inhibiting cell proliferation and inducing apoptosis in MV-4-11
cells. Figure 1a shows that a signiﬁcant growth inhibition was
achieved with 5 nM trabectedin or 2.5 μM 5-azacytidine. Figure 1b
reports the FACS analysis of cell cycle distribution of MV-4-11 cells
exposed to the equiactive concentration of trabectedin and
5-azacytidine for 24 h. Both drugs caused a delay in crossing G1
through S phase of the cell cycle. AnnexinV/PI ﬂow cytometric
assay revealed that trabectedin induced a remarkable apoptosis,
as the fraction of apoptotic cells evaluated at 24 h of treatment
was 70%, whereas this fraction was only 30% after 5-azacytidine
treatment (Figure 1c). These data were then conﬁrmed on
other cells representative of human myelomonocytic leukemia.
We obtained fresh leukemia cells from patients suffering from
JMML or CMML, respectively. In Figure 2, the induction of
apoptosis by 5 nM trabectedin treatment is shown in representa-
tive JMML (Figure 2a) and CMML (Figure 2b) primary cultures. The
effect was much greater than that of 2.5 μM 5-azacytidine used as
positive control, conﬁrming results obtained on the MV-4-11
cell line.
Altogether, these data conﬁrmed the high potency of
trabectedin on myelomonocytic leukemia cells, thus justifying
studies to elucidate its molecular mechanism.
Gene expression analysis was performed to investigate early
changes in transcriptional regulation induced by trabectedin
or 5-azacytidine after 6 and 24 h of treatment (Supplementary
Tables 1-2), according to the workﬂow reported in Figure 3.
Differential analysis revealed that MAFB (fold change 9.10) was the
most upregulated gene at 24 h (Figure 4a). We performed a
pathway analysis of deregulated genes identifying pathways
relevant to response and their activation state (Materials and
Methods). Among our results related to trabectedin, we found
the inhibition of the pathway related to M-phase at 24 h
(Figure 4b and c).
As it is reported that one of the main mechanisms of action of
trabectedin is the modulation of transcriptional regulators, we
focused our attention on transcription factors using an approach
based on master regulator analysis.
Results reported in Supplementary Table 3 show 12 signiﬁcant
(FDR-corrected P-valueo0.05) regulons at 6 h and 50 regulons at
24 h, both at FDRo5%.10 A number of transcription factors such
as JUNB, OVOL2, NR4A2, NR4A1, NFKB2, ID2 and ZBTB7B were found
to be enriched both at 6 h and at 24 h.
The most upregulated gene at 24 h, MAFB, seemed to have a
crucial role in the transcriptional network. First, at 6 h it was
present in the area of inﬂuence of four enriched transcription
factors, such as JUNB, ID2, ZBTB7B and NFKB2, (Figure 5a). Then, at
Figure 2. Apoptosis induced by 5 nM trabectedin and 2.5 μM 5-azacytidine (5-AZA) evaluated at 24 and 72 h after drug-treatment on cells
derived from either a JMML patient (a) or a CMML patient (b). Tables report the percentage of apoptotic and viable cells as average of three
different JMML (a) or CMML (b) patients at 24 and 72 h after treatment. R1: viable cells; R2: early apoptosis; R3: late apoptosis; R4: necrosis.
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24 h MAFB itself came up to be one of the most enriched
transcription factors, and at the same time it was also the highest
linked element of the network. Indeed, the most signiﬁcant genes
in the enrichment analysis of MAFB regulon showed a coherent
behavior in the expression values trend (Supplementary Figure 1).
MAFB belongs to the Maf leucine zipper transcription factor family,
which is expressed speciﬁcally in myeloid cells, where its
upregulation is correlated to monocyte differentiation for which
it plays a crucial role.20 Further studies by Gemelli and coworkers
demonstrated that MAFB is a master regulator of human
monocytopoiesis.21 Moreover, among these enriched transcription
factors, we found JUNB and FOSL2, whose protein product is
known to dimerize in the AP-1 complex transcription factor,
already described for its capacity to regulate monocyte
differentiation.21 Interestingly, Gemelli et al. investigated also the
genetic program activated by MAFB transduction and found that
the AP-1 complex transcription factor was directly upregulated by
MAFB.21 In order to assess the speciﬁcity of our results, we
compared the enrichment results of trabectedin at 24 h versus
control and of 5-azacytidine versus control at the same time point.
We found 14 transcription factors related only to trabectedin,
among which MAFB, and not to 5-azacytidine (Supplementary
Table 4).
We then searched for a gene proﬁle-based similarity of MV-4-11
cells treated with trabectedin with other known compounds,
using the Connectivity MAP.18 Irinotecan was the highest ranked
compound, before phenoxybenzamine, resveratrol and thiorida-
zine (Table 1). First, we focused our attention on irinotecan, the
highest ranked result, and thioridazine, because of the major
number of gene signatures correlated with our query (Table 1).
The ﬁrst drug, irinotecan, is a camptothecin analog developed as
anticancer in the early 1970s.22 As for all camptothecins, the
mechanism of action of irinotecan consists in the binding of DNA-
topisomerase I, causing the formation of a ternary complex with
DNA that is then converted in DNA breaks. The other correlated
compound, thioridazine, is a phenothiazine, acting as antagonist
of the dopamine receptor D2 family proteins.23 Although
commonly used as antipsychotic drug,23 previous studies have
revealed its anticancer action.23,24 The positive correlation
between trabectedin and these two drugs led us to think about
Figure 4. (a) Expression trend of the MAFB log2 ratio versus the reference (time point 0) from 6 to 24 h. (b) Pathways related to deregulated
genes with trabectedin treatment. FDR q-values are shown in logaritmic scale (base 10). (c) M-phase heatmap showing DEGs of trabectedin at
both 6 and 24 h annotated with the Reactome database.12
Figure 3. Workﬂow of the study.
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possible similarities between their mechanism of action. For this
reason, we performed two independent Gene Ontology analyses
on the gene signatures in common between trabectedin and
irinotecan and trabectedin and thioridazine, respectively. We
found that upregulated genes shared by both comparisons were
associated to the immune system, whereas downregulated genes
were related to the cell cycle process (Figure 6a and c,
respectively). Moreover, upregulated genes shared by trabectedin
and irinotecan were also associated with apoptosis (Figure 6b). In
order to conﬁrm these ﬁndings, we tested with qRT-PCR four
upregulated genes shared by trabectedin, irinotecan and thior-
idazine, but not differentially expressed with 5-azacytidine, that is
CCR7, GBP2, MDM2 and PROCR (Supplementary Figure 2). The
combination of trabectedin with irinotecan seems very interesting
since it has been recently found effective in preclinical models and
very recently there has been a preliminary indication of its clinical
Figure 5. MAFB networks. Enriched network at 6 h: ZBTB7B, JUNB, NFKB2 and ID2 hub genes; MAFB interacts in their network (a). Enriched
network at 24 h: MAFB is the most interconnected hub (b). Light blue, genes of the enriched network of Gene Set Enrichment Analysis (GSEA)
but not differentially expressed; from yellow to red, upregulated DEGs, the darker the color, the stronger the upregulation.
Table 1. First four results of the analysis computed with CMAP.
Rank Cmap name Mean n Enrichment P Speciﬁcity Percent non-null
1 Irinotecan 0.946 3 1 0 0.0364 100
2 Phenoxybenzamine 0.766 4 0.986 0 0.0446 100
3 Resveratrol 0.615 9 0.746 0 0.049 100
4 Thioridazine 0.421 20 0.642 0 0.0731 85
Cmap name, name of the perturbagen; mean, arithmetic mean of the connectivity scores for the related instances; n, number of instances connected to the
query; Enrichment, enrichment score; P, P-value; Speciﬁcity, estimation of the uniqueness of the connectivity between the query signature and a set of
instances; Percent non-null, percentage of instances in the set with a positive connectivity-score.
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Figure 6. Upregulated genes at 6 h shared between trabectedin and irinotecan and between trabectedin and thioridazine related to the
immune system process (a). Upregulated genes at 6h in common between trabectedin and irinotecan involved in to apoptotic process (b).
Downregulated genes at the same time shared by the three drugs associated to the cell cycle network (c). logFC, log2-transformed fold
change between treatment and control. Tick marks identify the presence of the gene signature for a speciﬁc drug, cross marks indicate
absence.
Figure 7. (a) Growth inhibition induced by different concentrations of thioridazine or SN-38. 10 μM and 5 nM represent the half-maximal
inhibitory (IC50) concentrations for thioridazine and SN-38, respectively. (b) Cell cycle perturbation induced by 10 μM thioridazide (B) and 5 nM
SN38 (C) evaluated at 24 h after drug-treatment compared to the control cells (A). (c) Apoptosis induced by 10 μM thioridazine (F) and 5 nM
SN38 (G) evaluated at 24 h after drug-treatment compared to the control cells (E). P.I., Propidium Iodide; R1, viable cells; R2, early apoptosis; R3,
late apoptosis; R4, necrosis.
Systems biology approach to trabectedin MoA
L Mannarino et al
6
The Pharmacogenomics Journal (2016), 1 – 8
efﬁcacy.25,26 The two drugs were used in a context of synergistic
action and molecularly targeted combination therapy, since
trabectedin blocks the EWS-FLI1 fusion gene activity, thus making
sarcoma cells more sensitive to irinotecan.25,27 On the other hand,
it has recently been demonstrated that thioridazine selectively
targets and impairs somatic cancer stem cells capable of in vivo
leukemic disease, while sparing normal cells.23 This drug also
suppresses proliferation and induces apoptosis in leukemic cells,
and it is the most effective compound among the other
phenothiazines.28 Moreover, Min et al.29 stated that thioridazine
stimulates TRAIL-mediated apoptosis in various human carcinoma
cells and this mechanism is also related to the action of
trabectedin on tumor-associated macrophages.5 These data have
prompted a clinical trial on the combination of thioridazine and
cytarabine for the treatment of relapsed or refractory Acute
Myeloid Leukemia (https://clinicaltrials.gov/show/NCT02096289).
From our analysis we also found a positive correlation with
phenoxybenzamine and resveratrol. While not the subject of our
study, both drugs have interesting features. The ﬁrst is a
noncompetitive antagonist of α1- and α2-adrenergic receptors,
30
whereas the second is a phytoalexin derived from the skin of
grapes and other fruits, which is known to have anti-inﬂammatory
and anti-oxidant effects,31 as well as being a chemopreventive
agent.32 Moreover, it was demonstrated that resveratrol has the
capacity to induce cell death in leukemia cells, in particular acute
myeloid leukemia cells, sensitizing them to the action of the
histone deacetylase inhibitors (HDACIs).33
Interestingly, among the biological functions that were shared
by irinotecan, thioridazine and trabectedin, such as immune
system process, immune response and apoptosis, we found the
involvement of the p53 effector CDKN1A gene. This gene, also
known as p21, is a cyclin-dependent kinase inhibitor, mainly
regulated at transcriptional level.34 Its main function is to
negatively modulate cell cycle progression and block it over the
G1-S phases.34 Our ﬂow cytometry experiments conﬁrmed the
inhibition of cell cycle exactly in these phases. Moreover, as
previously reported,34 CDKN1A is upregulated during hemato-
poietic differentiation, and this upregulation increases as cells
differentiate.35 In the same review, Steinman at al. conﬁrmed that
the upregulation on p21 in hematopoietic precursor cells leads to
the differentiation towards the myelomonocytic lineage. In our
study, CDKN1A resulted strongly upregulated at both 6 and 24 h
(log-fold change of nearly 10 and 15, respectively), and further
conﬁrmed also by qRT-PCR as shown in Supplementary Figure 3.
In the same experiment we also noticed that CDKN1A was not
signiﬁcantly expressed by 5-azacytidine treatment at both time
points. To further assess the speciﬁcity of CDKN1A, we performed
the same Gene Ontology analysis done on irinotecan and
thioridazine signatures using 5-azacytidine signatures. Only the
immune system process was shared between the two drugs
signatures. Therefore, this evidence indicates that the mechanisms
we observed in this cell line may be trabectedin speciﬁc.
Considering the similarities between the transcriptional effects
of trabectedin and those of camptothecin or thioridazine, we
wondered whether the drugs had also a similar effect on cell cycle
and apoptosis. We found that both thioridazine and SN-38, the
active metabolite of irinotecan, were able to induce a 50% growth
inhibitory effect evaluated at 24 h drug treatment (Figure 7a).
Thioridazine seemed to induce an arrest in G1 phase of the cell
cycle and a decrease in the rate of S phase progression towards
G2M phases. The active metabolite of irinotecan caused an
accumulation of cells in the G2M cell cycle phases (Figure 7b). We
then investigated the mechanism of cell death induced by these
two drugs by using annexinV/PI ﬂow cytometric assay. Both
thioridazine and SN-38 caused apoptosis in a 50% of the cells at
24 h of treatment (Figure 7c).
In summary, in this study we provided evidence that
trabectedin acts on myelomonocytic cells with a high degree of
speciﬁcity. First of all, our data indicate the possible central role of
the MAFB transcription factor given its very high upregulation
along the treatment and its dual role as regulator and regulated in
the network of transcriptional factors possibly implied in the
mechanism of action of the drug. We also showed that
trabectedin causes the inhibition of the cell cycle pathway with
a blockade of cells at the G1/S phase. This effect is possibly related
to upregulation of CDKN1A gene whose pleiotropic action is
involved also in cell cycle regulation.
Finally, the unexpected high correlation between trabectedin
and irinotecan or between trabectedin and thioridazine, although
requiring comparative experimental mechanistic data, invites to
speculate that there may be potential new rationals to combine
these drugs to obtain synergistic antitumor effects.
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